Print  |  Close

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer


Active: Yes
Cancer Type: Prostate Cancer
Unknown Primary
NCT ID: NCT06074510
Trial Phases: Phase IV Protocol IDs: PYL4301 (primary)
NCI-2024-00237
Eligibility: 18 Years and older, Male Study Type: Diagnostic
Study Sponsor: Lantheus Medical Imaging
NCI Full Details: http://clinicaltrials.gov/show/NCT06074510

Summary

The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can
safely and accurately detect the presence or absence of prostate cancer growing beyond
the prostate gland in men with favorable intermediate risk prostate cancer.

Participants will receive a single dose of PYLARIFY injection followed by a single
whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours after PYLARIFY injection.
Participants with positive study scan results that are suspicious for prostate cancer
outside of the prostate gland may be asked to undergo additional diagnostic test(s)
and/or recommend certain treatment(s) for prostate cancer within 2 to 90 days after the
study scan. Participants will be monitored for up to 12 months to collecting information
about treatment they receive for prostate cancer and results of regular PSA blood draws
if ordered by doctors for up to 12 months after the study scan.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.